UY37083A - Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso - Google Patents

Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso

Info

Publication number
UY37083A
UY37083A UY0001037083A UY37083A UY37083A UY 37083 A UY37083 A UY 37083A UY 0001037083 A UY0001037083 A UY 0001037083A UY 37083 A UY37083 A UY 37083A UY 37083 A UY37083 A UY 37083A
Authority
UY
Uruguay
Prior art keywords
ror1
antibodies
methods
bispectific
immunospecifically
Prior art date
Application number
UY0001037083A
Other languages
English (en)
Inventor
Ricardo Attar
T Baldwing Eric
M F Cardoso Rosa
Francois Gaudet
Benjamin Harman
Yingzhe Li
Ronan Mcdaid
F Nemeth-Seay Jennifer
C Pomerantz Steven
H Tam Susan
Wu Sheng-Jiung
Jinquan Luo
Mark Anderson Glenn
Alexey Teplyakov
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY37083A publication Critical patent/UY37083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En la presente descripción se proporcionan anticuerpos aislados que se unen inmunoespecíficamente a ROR1, anticuerpos biespecíficos que comprenden un sitio de unión al antígeno que se une inmunoespecíficamente a ROR1 y un sitio de unión al antígeno que se une inmunoespecíficamente a CD3, y métodos para su uso.
UY0001037083A 2016-01-22 2017-01-23 Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso UY37083A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662286121P 2016-01-22 2016-01-22

Publications (1)

Publication Number Publication Date
UY37083A true UY37083A (es) 2017-07-31

Family

ID=57915166

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037083A UY37083A (es) 2016-01-22 2017-01-23 Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso

Country Status (14)

Country Link
US (1) US20170210799A1 (es)
EP (1) EP3405493A1 (es)
JP (1) JP2019506158A (es)
KR (1) KR20180100238A (es)
CN (1) CN108495864A (es)
AR (1) AR107442A1 (es)
AU (1) AU2017209099A1 (es)
BR (1) BR112018014760A2 (es)
CA (1) CA3011419A1 (es)
MA (1) MA43658A (es)
MX (1) MX2018008934A (es)
TW (1) TW201734049A (es)
UY (1) UY37083A (es)
WO (1) WO2017127499A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016345681A1 (en) 2015-10-30 2018-05-10 Nbe-Therapeutics Ag Anti-ROR1 antibodies
JP7000660B2 (ja) 2016-01-20 2022-02-04 ザ スクリプス リサーチ インスティテュート Ｒｏｒ１抗体組成物及び関連の方法
MX2019015057A (es) 2017-06-23 2020-08-03 Velosbio Inc Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1).
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
WO2019016381A1 (en) * 2017-07-20 2019-01-24 Nbe-Therapeutics Ag MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
MX2020010881A (es) * 2018-04-18 2020-11-09 Exelixis Inc Construcciones de anticuerpos anti-ror.
WO2019225777A1 (ko) * 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
EP3831944A4 (en) * 2018-08-01 2021-11-10 National University Corporation Tokai National Higher Education and Research System ANTI-MMR1 MONOCLONAL ANTIBODY, ASSOCIATED FUNCTIONAL FRAGMENT, GENE, COMPOSITION OF DRUG ADMINISTRATION AND PHARMACEUTICAL COMPOSITION
AU2020217012A1 (en) 2019-02-01 2021-08-19 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
BR112021023026A2 (pt) * 2019-05-23 2022-01-04 Velosbio Inc Moléculas de ligação biespecíficas anti-ror1/anti-cd3
AU2020291487A1 (en) * 2019-06-14 2022-01-20 Abl Bio Inc. Bispecific antibody against alpha-syn/IGF1R and use thereof
WO2021101349A1 (ko) * 2019-11-21 2021-05-27 에이비엘바이오 주식회사 Ror1 및 b7-h3에 결합하는 항체, 이를 포함하는 항체-약물 접합체 및 그 용도
WO2021101346A1 (en) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
AU2021334677A1 (en) * 2020-08-24 2023-03-02 Epimab Biotherapeutics (Hk) Limited Anti-ROR1 antibodies and related bispecific binding proteins
GB202020154D0 (en) 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
JP2024504471A (ja) 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
WO2023000791A1 (en) * 2021-07-23 2023-01-26 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against ror1 and uses thereof
CN114605560B (zh) * 2022-03-30 2024-02-20 江苏蒙彼利生物科技有限公司 一种car-nk细胞及其制备方法与应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
MX2009010282A (es) 2007-03-29 2009-10-12 Genmab As Anticuerpos biespecificos y metodos para su produccion.
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2010124188A1 (en) * 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
EP2496605A1 (en) * 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
CN102712695B (zh) * 2009-12-18 2015-01-21 堪瑟拉公司 能够诱导细胞死亡的ror1生物抑制剂
BR112012017124C1 (pt) 2009-12-25 2021-08-31 Chugai Pharmaceutical Co Ltd Método para produzir e para purificar um multímero polipeptídico
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
CA2818992C (en) * 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
US20140170148A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
SG10201703425RA (en) 2011-05-21 2017-05-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
CA2844540C (en) 2011-08-23 2018-10-16 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
BR112014004166A2 (pt) 2011-08-23 2018-05-29 Roche Glycart Ag anticorpo biespecífico compreendendo pelo menos dois fragmentos fab, célula hospedeira procariótica ou eucariótica, metodo de produção de um anticorpo, imunoconjugado e invenção
ES2686327T3 (es) 2011-08-23 2018-10-17 Roche Glycart Ag Moléculas de unión a antígeno biespecíficas
ES2857734T3 (es) 2011-08-23 2021-09-29 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
DK2888283T3 (en) * 2012-08-24 2018-11-19 Univ California ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE
CA3211863A1 (en) * 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
CN105189557A (zh) 2013-03-15 2015-12-23 默克专利有限公司 四价双特异性抗体
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CN113416252A (zh) * 2014-05-29 2021-09-21 宏观基因有限公司 三特异性结合分子和其使用方法

Also Published As

Publication number Publication date
AU2017209099A1 (en) 2018-08-02
AR107442A1 (es) 2018-05-02
EP3405493A1 (en) 2018-11-28
US20170210799A1 (en) 2017-07-27
CA3011419A1 (en) 2017-07-27
TW201734049A (zh) 2017-10-01
MA43658A (fr) 2018-11-28
WO2017127499A1 (en) 2017-07-27
MX2018008934A (es) 2019-03-28
JP2019506158A (ja) 2019-03-07
KR20180100238A (ko) 2018-09-07
BR112018014760A2 (pt) 2018-12-26
CN108495864A (zh) 2018-09-04

Similar Documents

Publication Publication Date Title
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
ECSP17081420A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CL2019001198A1 (es) Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple.
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
CR20140585A (es) Proteinas de union a antigeno st2
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
IL264334B2 (en) Anti-GPRC5D antibodies, bispecific antigen-binding molecules that bind GPRC5D and CD3 and uses thereof
BR112017011914A2 (pt) ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso?
MA43164A (fr) Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
UY37761A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CL2016001723A1 (es) Molécula de anticuerpo que se une al receptor de muerte programada 1 (pd-1) y usos.
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
CU20170074A7 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
EA201691321A1 (ru) Антитела и способы их применения
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas